{
    "nct_id": "NCT06158841",
    "official_title": "A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance of <= 2.\n* Diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) during or after the participant's last treatment as stated in the protocol.\n* Must have measurable disease with at least 1 of the following assessed within 28 days of enrollment:\n\n  * Serum M-protein >= 0.5 g/dL (>= 5 g/L).\n  * Urine M-protein >= 200 mg/24 hours.\n  * In participants without measurable serum or urine M protein, serum free light chain (FLC) >= 100 mg/L (10 mg/dL) (involved light chain)and an abnormal serum kappa lambda ratio.\n* Must have received at least 2 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide (IMiD), and an anti-CD38 monoclonal antibody (mAb).\n* Must be eligible to receive the Investigator's choice standard available therapy (SAT) based on approved prescribing information, previous MM treatment history, and institutional guidelines.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Clinically significant (per Investigator's judgment) drug or alcohol abuse within the last 6 months.\n* Clinically significant conditions such as but not limited to the following: neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, pulmonary, or hepatic disease within the last 6 months that would adversely affect the participant's participation in the study.\n* Central nervous system involvement of MM.\n* Has received B-cell maturation antigen (BCMA)-targeted therapy.",
    "miscellaneous_criteria": ""
}